The Deal Can Die Before the Regulator Says No

GlobalWafers’ €4.35 billion pursuit of Siltronic shows how a regulator can defeat a transaction simply by running out the clock. The lesson is not that sensitive assets are unbuyable. Buyers keep pursuing them precisely because chips, ports, data and supply chains matter commercially and strategically. But Trieste, where a Maersk/HHLA transaction was screened and cleared, shows that clearance remains possible. The difference lies in the asset, the buyer’s ownership chain, the political setting, the likely remedies and, above all, whether the deal can survive the wait.

On 31 January, Taiwan’s GlobalWafers was still waiting.

It had agreed to buy Siltronic AG, the Munich-based maker of silicon wafers used in semiconductor production, for €4.35 billion. More than a year had passed in Germany’s foreign-investment review. Yet the German regulator did not issue a decision before the offer expired.

That was enough. The acquisition failed.

No dramatic prohibition. No public final refusal. Just a clock reaching midnight before a buyer could close.

Siltronic became the €4.35 billion case study in how an unresolved review can outlast an offer. Photo: Christian Fohrer / Pexels, Pexels licence (free commercial use).

For anyone treating foreign-investment screening as a standard post-signing formality, this is the uncomfortable question: what is an approval worth if it arrives after the deal has already died?

Most investors still picture national-security review as a narrow checkpoint for defence contractors. The lawyers identify the filing, submit it after the agreement is signed, and wait. At worst, there is paperwork and a modest delay.

That picture is now too small. The Council of the European Union’s June 2026 update extends the European framework across technology, energy, transport, digital infrastructure, dual-use goods and critical raw materials. It also captures investments made through EU subsidiaries.

The central fact is simpler: approval risk is not only a legal question. It is transaction risk. It changes the price a buyer can justify, whether financing can wait, and who pays when the deal fails.

The clock is part of the price

GlobalWafers and Siltronic are the cleanest demonstration because nothing needed to be formally banned for the investment thesis to collapse. Hogan Lovells noted that Germany counts semiconductors among 16 critical technologies subject to cross-sector review.

A silicon-wafer manufacturer may not sound like a military asset in everyday language. In the supply chain for chips, it plainly mattered.

The lesson was not that a Taiwanese buyer could never buy in Germany. It was harsher. A strategically sensible buyer can face a timetable that the commercial agreement cannot survive.

At first glance, a long review looks like an inconvenience. It is not. Imagine you are the seller. Your business is tied up while the offer runs. Employees, customers and lenders know there is a transaction, but nobody knows whether it will close. If the offer has an expiry date, delay is part of the value calculation.

Here is a simple illustrative example. A buyer agrees to pay £100 million and arranges £60 million of financing at an annual cost of 8%, expecting a three-month route to closing. If regulatory review stretches the period to 12 months, the annualised cost of keeping that £60 million available rises from £1.2 million for three months to £4.8 million for a year. That is an extra £3.6 million.

The buyer may absorb it. More often, it will seek to recover it through a lower price, tougher terms or both. If the full extra cost is reflected in price, the seller’s expected £100 million becomes £96.4 million. And that is before considering the risk that the financing itself expires or conditions are imposed.

Delay becomes the mechanism that removes value.

This is where most people stop looking. They ask, “Will the authority block us?” The better question is, “How long can this deal remain alive, and who bears the cost if a decision or remedy arrives too late?”

That is why a long-stop date, the last date by which a deal must close, belongs beside the purchase price. So does a reverse-break fee, a payment the buyer may owe if regulatory failure prevents closing. Hogan Lovells’ account of GlobalWafers pointed to break-fee language and remedy negotiations shaped by screening uncertainty.

GlobalWafers discovered that a buyer can lose a strategic deal without receiving a formal prohibition. Photo: Dr. Mohammad Hoque / Pexels, Pexels licence (free commercial use).

Why buyers still want the assets regulators fear

There is an easy but wrong conclusion to draw from Siltronic: avoid sensitive assets.

Buyers keep pursuing them because sensitivity is often another word for importance. A company supplying semiconductor materials sits in a valuable part of a technology chain. A port connects trade routes and supply capacity. A chip developer may hold know-how with uses beyond its immediate commercial market.

The same feature can produce two opposite reactions. A buyer sees strategic commercial value. A regulator sees strategic national exposure.

That tension is why these deals are pursued despite delay and remedy risk. The buyers are not necessarily blind to the danger. They may believe the asset is sufficiently important to justify a difficult process, or that a clearance can still be achieved on acceptable terms. Trieste shows that this is not wishful thinking in every case.

But it also means the buyer must price the risk honestly. A sensitive asset bought at an ordinary, clean-clearance valuation can become a bad deal even if approval eventually arrives.

The chip deal where the label did not matter

Consider Lumileds, the Dutch firm targeted in a proposed acquisition by China’s Sanan Optoelectronics. Tom’s Hardware reported that CFIUS, the US body that reviews certain foreign investments, blocked the proposed transaction because Lumileds’ gallium-nitride chips had military applications.

The important correction is that this should not be treated as a $239 million case. The cited account does not support using that figure as the deal’s value. The useful fact is the regulatory outcome: a proposed acquisition involving semiconductor technology was blocked over the strategic uses of the technology.

Gallium nitride, or GaN, is a semiconductor material. You do not need a technical degree to understand the issue. If a component can have military applications, a regulator may see strategic capability where a buyer sees an ordinary commercial product.

Lumileds showed why the strategic use of a chip can matter more than the target’s commercial label. Photo: Timothy Huliselan / Pexels, Pexels licence (free commercial use).

Here is the twist: the target did not need to call itself a defence company to create screening risk. Its place in the technology chain was enough.

That matters for startups and private companies as much as public acquisitions. A company raising money should not ask only whether it sells to governments. It should examine what technology it holds, what data it controls, where that technology can be used and which rights a foreign investor will receive.

For founders, this reaches beyond a sale process. The control you give up may not be in the cap table. It can be embedded in investor rights, information access and the ownership chain behind the capital.

The ownership chain that did not settle the question

The Xella case in Hungary exposed another false comfort: that an EU layer makes foreign-investment scrutiny disappear.

Xella Magyarország, a Hungarian mining business, was involved in a transaction connected to a third-country investor through an ownership chain including Irish and Bermuda corporate entities. Hungary blocked the transaction under its screening law. In July 2023, the European Court of Justice found that Hungary’s application of the law breached EU freedom of establishment.

The European Parliamentary Research Service documented the case as a warning about the collision between national screening powers and European legal protections.

That is a mixed outcome, not a clean victory for either side. The state’s intervention did not survive judicial scrutiny. Yet the case shows that indirect ownership and corporate layering can draw official attention, including in raw materials rather than headline-grabbing defence technology.

Put Germany, the United States and Hungary side by side and a pattern appears that none of the reports states quite this plainly: screening regimes do not merely inspect the thing being bought. They inspect the path by which influence travels to it.

A buyer’s incorporation address may be the least interesting fact in the file. Regulators can care about ultimate owners, state relationships, the rights that come with a stake and the strategic function of the target.

There is a second lesson. Screening risk is real, but regulators are not automatically right. Xella shows that an intervention can be overturned. Litigation may correct an overreach, but it does not restore lost certainty or make financing deadlines wait politely.

Trieste was not a rivalry story

The story is not that every cross-border deal in a sensitive sector is doomed. Piattaforma Logistica Trieste, a logistics asset at Italy’s Port of Trieste, is the necessary corrective.

The Italian ports research records a Maersk/HHLA bid for Piattaforma Logistica Trieste that was screened and cleared. Maersk is a global shipping company. HHLA is involved in port operations. The evidence does not describe separate Maersk and HHLA bids, nor does it establish that they were competing for the asset. For this case, they should be understood as the parties identified in the same screened transaction.

That clearance matters. It keeps the GlobalWafers lesson honest. Screening is not itself a veto. A transaction involving a strategically significant asset can proceed where authorities accept the buyer and the terms.

But research published by Springer found that very few Italian port cases were formally screened until 2022. Political conditions then shifted. Port and logistics investments encountered more active scrutiny, while some Chinese investors avoided screening.

Why screen an asset already subject to concession and tender systems? Because a port is more than commercial property. It is a route into national supply chains, transport capacity and waterfront infrastructure.

We expected concession rules to make the screening question less important. The evidence suggests the opposite. Sector approvals do not necessarily replace foreign-investment review. They can sit alongside it, creating another decision-maker and another timetable.

The European Parliamentary Research Service found that 55% of notified EU cases were formally screened in 2022, up from 29% in 2021 and 20% in 2020. Of the 2022 cases, 9% were cleared with conditions and 1% were blocked.

A condition can be more important than a block. It may alter what the buyer thought it was buying. The research does not supply a universal menu of remedies, and jurisdictions differ. The commercial implication is still clear: underwrite not only a clean clearance, but whether the deal remains worthwhile if the authority changes it.

When the target changes category

South Korea’s Magnachip Semiconductor case adds the most unnerving possibility: a target can become sensitive after a transaction has begun.

Wise Road, a Chinese private-equity buyer, pursued Magnachip, a Korean developer of OLED driver chips used in display technology. South Korea’s Ministry of Trade, Industry and Energy initially did not classify the technology as National Core Technology.

After requesting technical information, the ministry classified OLED driver chips as National Core Technology and began a security review. The proposed transaction did not close.

Magnachip’s proposed acquisition encountered review after OLED driver-chip technology was classified as National Core Technology. Photo: Raimond Spekking / Wikimedia Commons, CC BY-SA 4.0.

This is a different problem from misreading a published list of sensitive sectors. More facts can change the regulator’s view.

For transaction documents, that means planning for movement. The buyer and seller need to decide in advance what happens if a review lengthens, if more information is requested, or if an authority seeks a remedy. Debt does not become patient merely because a regulator asks better questions.

What operators should put in the data room

Foreign-investment screening should be treated as a pre-signing underwriting exercise. Not “Do we file?” but “Can this transaction survive the filing?”

Start with a sensitivity map. Identify the technology, data, infrastructure, supply-chain role and customer relationships that could make the company strategically relevant. Then build an ownership and rights map. Track who ultimately owns the investing entities, who has governance rights and who receives information.

Finally, stress-test the timetable. Ask what happens if closing is delayed, financing becomes unavailable or a buyer must accept conditions. A business can be profitable and still lose value if the buyer cannot transfer it cleanly. That is the same question behind whether a business is transferable.

GI Network's view: A screening filing is not a box to tick after valuation is set. It is evidence about whether the valuation can survive contact with the state.

GI Network would identify the target’s strategic sensitivities and trace the ownership and rights behind prospective capital. We would test whether cash flows and the financing timetable can withstand a delayed or conditioned closing, align deal materials with likely investor objections, and structure outreach around capital providers whose ownership profile and risk appetite fit the asset.

What experienced investors see earlier

Sophisticated investors are not necessarily better at predicting politics. They are better at refusing to pretend politics is outside the model.

A reverse-break fee gives a seller some compensation if the buyer cannot obtain approval. A remedy commitment shows how much the buyer is prepared to surrender to close. A long-stop date reveals whose clock matters most.

These are not boilerplate clauses. They are the agreement’s hidden forecast of regulatory risk.

Investors should ask whether a stake comes with rights that could matter, whether the capital base introduces a difficult ownership question, and whether technical detail could change how the target is classified. As investment committees often discover too late, the deal rarely fails in the first presentation. It fails when someone asks the question the headline valuation concealed.

The Survival Matrix

Use the Survival Matrix before committing to a cross-border transaction:

1. 1.Sensitive asset: What does the target actually do, hold or enable?
2. 2.Visible buyer: Who ultimately owns or influences the capital, and what rights travel with it?
3. 3.Real process: Which jurisdictions can review it, and can the parties close before approval?
4. 4.Workable remedy: Would the deal still be worth doing after conditions or a changed classification?
5. 5.Funded time: Can the agreement, financing and seller relationship survive the realistic timetable?

If one answer is weak, the risk is not merely that a regulator may say no. The risk is that the transaction has been priced as if time, ownership and politics were someone else’s problem.

Siltronic shows what happens when they are not.